COVID-19 in Patients on Maintenance Dialysis in the Paris Region

Sarah Tortonese, Ivan Scriabine, Louis Anjou, Christopher Loens, Arthur Michon, Mohammed Benabdelhak, Sarah Ouali, Gabriel Morin, Marwa Laifi, Hélène Dobosziewicz, Matthieu Guillet, Manon Dekeyser, Liem Binh Luong Nguyen, Anne Grünenwald, Julien Dang, Geoffroy Desbuissons, Laurent Becquemont, Renaud Snanoudj, Christophe Legendre, Hadia Hebibi, Edouard Lefèvre, Séverine Beaudreuil, Mohamad Zaidan, AP-HP/Universities/Inserm COVID-19 research collaboration, Sarah Tortonese, Ivan Scriabine, Louis Anjou, Christopher Loens, Arthur Michon, Mohammed Benabdelhak, Sarah Ouali, Gabriel Morin, Marwa Laifi, Hélène Dobosziewicz, Matthieu Guillet, Manon Dekeyser, Liem Binh Luong Nguyen, Anne Grünenwald, Julien Dang, Geoffroy Desbuissons, Laurent Becquemont, Renaud Snanoudj, Christophe Legendre, Hadia Hebibi, Edouard Lefèvre, Séverine Beaudreuil, Mohamad Zaidan, AP-HP/Universities/Inserm COVID-19 research collaboration

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) represents a serious threat to patients on maintenance dialysis. The clinical setting, mortality rate, and prognostic factors in these patients have not been well established.

Methods: We included all dialyzed patients with COVID-19 referred to our dialysis center between March 11 and April 11, 2020. Data were obtained through the review of the medical records and were censored at the time of data cutoff, on May 11, 2020.

Results: Forty-four patients on maintenance dialysis with COVID-19 were referred to our dialysis unit during the COVID-19 epidemic. Median age was 61 years (interquartile range [IQR]: 51.5-72.5); 65.9% were men. Comorbidities included hypertension (97.7%), diabetes mellitus (50%), and chronic cardiac (38.6%) and respiratory (27.3%) diseases. Initial symptoms were fever (79.5%), shortness of breath (29.5%), cough (43.2%), and diarrhea (13.6%). Three profiles of severity were distinguished based on the World Health Organization (WHO) progression scale. Forty-one (93.2%) were hospitalized and only 3 were maintained on outpatient hemodialysis. Thirty-three (75%) patients required oxygen therapy, including 15 (45.5%) who were referred to the intensive care unit. Overall, 27.3% of patients died, and 58.5% were discharged from hospital, including only 2 (13.3%) of those admitted to the intensive care unit. By multivariate analysis, cough, thrombopenia <120 g/l, lactate dehydrogenase (LDH) level greater than 2 times the upper limit of normal, and blood C-reactive protein (CRP) >175 mg/l were significantly associated with death.

Conclusion: A major outbreak of COVID-19 occurred in the Paris region, and spread among dialyzed patients. Our study underscores the severity of COVID-19 in these patients and identified prognostic markers.

Keywords: COVID-19; coronavirus; hemodialysis; kidney; peritoneal dialysis.

© 2020 International Society of Nephrology. Published by Elsevier Inc.

Figures

Figure 1
Figure 1
Cumulative incidence of COVID-19 dialyzed patients referred to the in-hospital dialysis unit of Bicêtre University Hospital (APHP).
Figure 2
Figure 2
Comparison of main laboratory data between admission and worst value by World Health Organization (WHO) score group. (a) Hemoglobin level (g/dl) on admission (Hbadm) and minimum (Hbmin) value during hospitalization. (b) Lymphocyte count (g/l) on admission (Lymphadm) and minimum (Lymphmin) value during hospitalization. (c) Platelet count (g/l) on admission (Platadm) and minimum (Platmin) value during hospitalization. (d) Blood C-reactive protein level (mg/l) on admission (CRPadm) and maximum (CRPmax) value during hospitalization. (e) Lactate dehydrogenases level (UI/l) on admission (LDHadm) and maximum (LDHmax) value during hospitalization.
Figure 3
Figure 3
Overall severity by World Health Organization (WHO) progression scale and impact on mortality.
Figure 4
Figure 4
Kaplan-Meier survival curves of significant covariates associated with death by multivariate analysis. Hazard ratios (HR) and 95% confidence intervals (CI) are detailed after adjustment for age. CRP, C-reactive protein; LDH, lactate dehydrogenase.

References

    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Chen T., Wu D., Chen H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
    1. Lauer S.A., Grantz K.H., Bi Q. The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577–582.
    1. Yang X., Yu Y., Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–481.
    1. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
    1. Young B.E., Ong S.W.X., Kalimuddin S. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323:1488–1494.
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242.
    1. Livingston E., Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323:1335.
    1. Wu C., Chen X., Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:1–11.
    1. Kliger A.S., Silberzweig J. Mitigating risk of COVID-19 in dialysis facilities. Clin J Am Soc Nephrol. 2020;15:707–709.
    1. Centers for Disease Control and Prevention Coronavirus Disease 2019 (COVID-19) Published February 11, 2020. Available at:
    1. COVID-19. Available at:
    1. COVID-19 News and Information. ERA-EDTA. Available at:
    1. Ma Y, Diao B, Lv X, et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China [e-pub ahead of print]. medRxiv.. Accessed April 26, 2020.
    1. Scarpioni R., Manini A., Valsania T. Covid-19 and its impact on nephropathic patients: the experience at Ospedale “Guglielmo da Saliceto” in Piacenza. G Ital Nefrol. 2020;37 2020-vol2.
    1. Alberici F., Delbarba E., Manenti C. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020;98:20–26.
    1. Goicoechea M., Cámara L.A.S., Macías N. COVID-19: Clinical course and outcomes of 36 maintenance hemodialysis patients from a single center in Spain. Kidney Int. 2020;98:27–34.
    1. Fisher M, Yunes M, Mokrzycki MH, et al. Chronic hemodialysis patients hospitalized with COVID-19 - Short-term outcomes in Bronx, New York [e-pub ahead of print]. Kidney360.. Accessed June 4, 2020.
    1. Wang R., Liao C., He H. COVID-19 in hemodialysis patients: a report of 5 cases. Am J Kidney Dis. 2020;76:141–143.
    1. Wilson N., Kvalsvig A., Barnard L.T., Baker M.G. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis. 2020;26:1339–1441.
    1. Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde. Available at: . Accessed May 12, 2020.
    1. Grasselli G., Pesenti A., Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020;323:1545–1546.
    1. Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775–1776.

Source: PubMed

3
Abonner